Corrigendum: HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma (Neuro-Oncology DOI: 10.1093/neuonc/not131);HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma

Neuro-Oncology

Volumn 15, Issue 12, 2013, Pages 1595-1603

  Zhang, Jun Xia ^a,b   Han, Lei ^a   Bao, Zhao Shi ^c   Wang, Ying Yi ^b   Chen, Lu Yue ^a   Yan, Wei ^c   Yu, Shi Zhu ^a   Pu, Pei Yu ^a   Liu, Ning ^b   You, Yong Ping ^b   Jiang, Tao ^c   Kang, Chun Sheng ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Glioma; HOTAIR; Molecular subtype; Survival

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; HOX TRANSCRIPT ANTISENSE INTERGENIC RNA; LONG UNTRANSLATED RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCOMB REPRESSIVE COMPLEX 2; TEMOZOLOMIDE; TENSIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CELL; CANCER DIAGNOSIS; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OLIGODENDROGLIOMA; TUMOR VOLUME;

CELL CYCLE; GLIOMA; HOTAIR; MOLECULAR SUBTYPE; SURVIVAL;

ADULT; ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; MALE; MESODERM; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891852307     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nox190     Document Type: Erratum

References (22)

1. Sana J, Faltejskova P, Svoboda M, Slaby O. Novel classes of non-coding RNAs and cancer. J Transl Med. 2012;10:103.
2. Cano A, Nieto MA. Non-coding RNAs take centre stage in epithelial-tomesenchymal transition. Trends Cell Biol. 2008;18:357-359.
3. Huang K, Zhang JX, Han L, et al. MicroRNA roles in beta-catenin pathway. Mol Cancer. 2010;9:252.
4. Wang WX, Huang Q, Hu Y, Stromberg AJ, Nelson PT. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol. 2011;121:193-205.
5. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155-159.
6. Zhang J, Zhang A,Wang Y, et al. New insights into the roles of ncRNA in the STAT3 pathway. Future Oncol. 2012;8:723-730.
7. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.
8. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354-361.
9. Han L, Zhang K, Shi Z, et al. LncRNAprofile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. Int J Oncol. 2012;40:2004-2012.
10. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331:139-146.
11. HegiME, Janzer RC, Lambiv WL, et al. Presence of an oligodendrogliomalike component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/NCIC-CE.3 trial. Acta Neuropathol. 2012;123:841-852.
12. Zhang JX, Zhang J, YanW, et al. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association withnewmolecular subtypes of glioblastoma. Neuro Oncol. 2013;15:279-289.
13. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-15550.
14. Gupta RA, Shah N,Wang KC, et al. Long non-codingRNAHOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464:1071-1076.
15. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17:98-110.
16. YanW, ZhangW, You G, et al. Molecular classification of gliomas based on whole genome gene expression: A systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol. 2012;14: 1432-1440.
17. Kogo R, Shimamura T,Mimori K, et al. Long noncodingRNAHOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71: 6320-6326.
18. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17:2613-2618.
19. Geng YJ, Xie SL, LiQ,MaJ,WangGY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res. 2011;39:2119-2128.
20. Li D, Feng J,WuT, et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol. 2013;182:64-70.
21. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell. 2011;44:667-678.
22. Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32:1616-1625.